High dose EC x 3 supported by PBSC vs. EC/AC x 4 followed by CMF as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (less than 65 years) patients

Study Chairs
Dr. Russel Basser - Melbourne, Australia
Prof. Monica Castiglione - Bern, Switzerland

Dr. Zhouxin Sun

Lead Trial Coordinator
Holly Shaw

Director of Data Management
Lynette Blacher

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
July 1995

Date of Closure
March 15, 2000

Targeted Accrual
300 patients

Final Accrual
344 patients

Date of Discontinued Follow-up

December 31, 2011

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login